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ABSTRACT.
Purpose: To evaluate the eﬃcacy of photobiomodulation (PBM) treatment for
patients with dry age-related macular degeneration (AMD).
Methods: Assessments on 42 eyes with dry AMD (age related eye disease study
(AREDS) 2–4) were conducted. Multiwavelength light emitting diode (LED)
light comprising of yellow (590 nm), red (670 nm) and near-infrared (790 nm)
bandwidths was applied to subjects’ eyes for a treatment course of 3 weeks.
Outcome measures were changes in best-corrected visual acuity (BCVA),
contrast sensitivity (CS), drusen volume and central drusen thickness.
Results: Signiﬁcant improvement in mean BCVA of 5.90 letters (p < 0.001) was
seen on completion of the 3-week treatment and 5.14 letters (p < 0.001) after
3 months. Contrast sensitivity improved signiﬁcantly (log unit improvement of
0.11 (p = 0.02) at 3 weeks and 3 months (log unit improvement of 0.16
(p = 0.02) at three cycles per degree. Drusen volume decreased by 0.024 mm3
(p < 0.001) and central drusen thickness was signiﬁcantly reduced by a mean of
3.78 lm (p < 0.001), while overall central retinal thickness and retinal volume
remained stable.
Conclusion: This is the ﬁrst study demonstrating improvements in functional
and anatomical outcomes in dry AMD subjects with PBM therapy. These
ﬁndings corroborate an earlier pilot study that looked at functional
outcome measures. The addition of anatomical evidence contributes to
the basis for further development of a non-invasive PBM treatment for dry
AMD.
Key words: age-related macular degeneration – contrast – drusen – photobiomodulation – sensi-
tivity – visual acuity
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Introduction
Age-related macular degeneration
(AMD) is a retinal degenerative disease
that causes irreversible and profound
vision loss in people over the age of
60 years (Evans &Wormald 1996) with
estimates of AMD patients nearing 50
million worldwide. It is emerging as one
of the primary causes of vision impair-
ment in the developed world (Gordois
et al. 2012).
Age-related macular degeneration
(AMD) occurs in two major forms:
exudative (wet) and atrophic (dry)
AMD. Dry AMD is characterized by
drusen, retinal pigment epithelial (RPE)
cell atrophy and subjacent photorecep-
tor degeneration. Factors involved in
causing RPE cell injury and dysfunc-
tion have been shown to include mito-
chondrial dysfunction, oxidative stress,
inﬂammation and genetic disposition
(Qin & Rodrigues 2008).
The vast majority of AMD patients
suﬀering from dry AMD, marked by
RPE dysfunction with drusen forma-
tion and eventual retinal atrophy, have
no eﬀective treatment options other
than lifestyle modiﬁcation and the use
of vitamins (Davis et al. 2005).
A safe and globally expanding medical
intervention is the use of low-level laser
(light) therapy (LLLT) that now includes
diabetic wound repair, arthritis, cancer
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radiationprotection (oralmucositis), den-
tal, sports medicine and skeletal muscle
disorders (trauma and pain). Low-level
laser therapy exerts its beneﬁcial eﬀects
through increased blood ﬂow and stimu-
lation of cellular functions, a process
called photobiomodulation (PBM).
Photobiomodulation (PBM) involves
the use of visible to near-infrared (NIR)
light (500–1000 nm) produced by a
laser or non-coherent light sources such
as light emitting diodes (LEDs) applied
to the body to produce beneﬁcial cellu-
lar eﬀects. Light in this range penetrates
tissue depending on the wavelength and
stimulates cellular function via activa-
tion of photoacceptors (Rojas et al.
2008; Tata & Waynant 2010; Rojas &
Gonzalaz-Lima 2011).
Published studies demonstrate that
mitochondrial cytochrome C oxidase
(CCO) is a key photoacceptor of light
at thesewavelengthsand improvesblood
ﬂow and ATP formation, enhances O2
binding and reduces oxidative stress and
inﬂammation (Karu et al. 1995; Karu&
Kolyakov 2005; Wong-Riley et al.
2005).
Although early studies identiﬁed
mitochondrial CCO as an endogenous
photoacceptor for PBM, the cellular
and molecular mechanisms underlying
PBM are better understood. Recent
ﬁndings provide important new insight.
First, nitric oxide has been implicated.
Second, CCO, an enzyme known to
reduce oxygen to water at the end of the
mitochondrial respiratory chain, has
been shown to have a new enzymatic
activity – the reduction of nitrite to
nitric oxide. This nitrite reductase activ-
ity is elevated under hypoxic conditions
but also occurs under normoxia. And
third, low-intensity light regulates nitric
oxide synthesis by CCO without alter-
ing its ability to reduce oxygen. From
these ﬁndings, Poyton and Ball have
proposed that CCO functions in PBM
by regulating nitric oxide, a signalling
molecule which can then function in
both intra- and extracellular signalling
pathways. They also propose that the
eﬀectiveness of PBM is under the con-
trol of tissue oxygen and nitrite levels
(Poyton & Ball 2011).
Previous reports have suggested
that phagocytosis is reduced by age-
related increased oxidative stress in
AMD. Investigations on PBM in the
human retinal pigment epithelial
(ARPE-19) cell lines demonstrate PBM-
improved phagocytosis, which is reduced
under oxidative stress (Fuma et al.
2015).
Multiple preclinical animal models
of ocular disease or disorders show
PBM to be beneﬁcial. These eﬀects
include reductions in damage observed
in methanol toxicity, laser burn, com-
plement factor H knockout inﬂamma-
tory, bright light damage, retinitis
pigmentosa and diabetic retinopathy
animal models (Eells et al. 2003; Albar-
racin et al. 2011; Tang et al. 2013;
Gkotsi et al. 2014). Photobiomodula-
tion (PBM) can increase mitochondrial
ATP, replication, density and activity
and increase RNA and protein synthe-
sis (Passarella & Karu 2014).
McDaniels has reported the eﬀect of
PBM using 590/870-nm light on the
expression of VEGF in 0- and 4-week
cultured humanRPE cells where up to a
sevenfold decrease in VEGF expression
was seen. McDaniels also reported the
response of PBM using 670-nm light on
the revitalization of RPE cells after an
acute high-dose blue light injury. Fol-
lowing blue light insult at 30 J/cm2, it
was observed that 90% of RPE
cells died. This is in contrast to the 5%
of cells that died with blue light
insult followed by red light therapy
(LED photomodulation ‘reverses’ acute
retinal injury, ASLMS Conference,
2006).
Ivandic and Ivandic show clinically
that PBM with a laser diode aimed at
the macular area signiﬁcantly improves
visual acuity in a case series of both dry
and wet AMD subjects. Visual acuity
(VA) in the control group remains
unchanged. No adverse eﬀects were
observed in patients undergoing PBM
therapy (Ivandic & Ivandic 2008).
Merry et al. have previously pre-
sented results of a PBM pilot study in a
small cohort of dry AMD patients, The
Toronto and Oak Ridge Photobiomod-
ulation Study for Dry Age-Related
Macular Degeneration (TORPA) that
demonstrated statistically signiﬁcant
improvements in early treatment dia-
betic retinopathy study (ETDRS) best-
corrected visual acuity (BCVA) and
contrast sensitivity (CS) (PBM as a new
treatment for dry AMD, ARVO,
2012). Further, PBM has recently been
shown to reduce non-central diabetic
macular oedema in a case series (Tang
et al. 2014).
Therefore, a growingbodyof evidence
suggests that PBM treatment could have
a beneﬁcial role in dryAMD,a condition
characterized by mitochondrial dysfunc-
tion, oxidative stress and inﬂammation
within the RPE cell layer, choriocapil-
laris and neuroretina.
We report the ﬁndings from 42 eyes in
an interventional, longitudinal case ser-
ies. This study evaluated functional and
pathological end-points including retinal
and drusen morphology using Spectral
domain-Optical coherence tomography
(SD- OCT). We demonstrate that PBM
has the potential to signiﬁcantly improve
both functional clinical and morpholog-
ical outcomes in dry AMD.
Materials and Methods
Patient selection and setting
Subjects ≥50 years of age with dry
AMD were eligible for study participa-
tion and were enrolled at the practices
of Drs. Merry and Devenyi within a
time period of 2011–2015.
Subjects were treated oﬀ-label with
availableLEDinstrumentsapprovedfor
other indicationsbytheFDAandHealth
Canada. Subjects who met the inclusion
criteria and gave written informed
consent underwent PBM with three
treatment sessions perweek for 3 weeks.
Optical coherence tomography retinal
images and fundus autoﬂuorescence
(FAF) were obtained at baseline (BL),
immediately following the initial 3-week
treatment course at visit 1 and at a
subsequent visit at 3 months (visit 2).
Formal data collection with indepen-
dent OCT and FAF analysis was con-
ducted to evaluate both clinical and
anatomical beneﬁts of PBM. The study
analysis protocol was approved by the
Chesapeake Investigational Review
Board and performed in adherence to
the guidelines of the Declaration of
Helsinki.
Inclusion criteria were dry AMD,
AREDS grades (according to the
American Academy of Ophthalmol-
ogy) 2, 3 and 4 [geographic atrophy
(GA), no choroidal neovascularization
(CNV)] and a BCVA of letter score 50
(logMAR 1.0, Snellen 20/200) or bet-
ter. A wide range of dry AMD cate-
gories were included as the study goal
was to explore the potential beneﬁt of
PBM in varying stages and severity of
AMD. Subjects with previous/active
wet AMD, a history of epilepsy, other
retinal diseases, signiﬁcant media opac-
ity and cataracts worse than grade 2
(LOCS III) were excluded.
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PBM intervention
After carefully and extensively review-
ing the available literature and the so
far proposed mode of actions of the
diﬀerent evaluated wavelengths, the
authors decided to use a multiwave-
length approach as this would poten-
tially aﬀect diﬀerent cellular targets
and should therefore confer greater
beneﬁt than a single wavelength. Two
separate devices were required to pro-
vide the multiple wavelengths. Both
devices were FDA and Health Canada-
approved for other conditions.
The PBM intervention consisted of
three distinct wavelengths in the yellow
(590 nm), red (670 nm) and NIR
(790 nm) range, chosen for their beneﬁts
on cellular targets involved in the disease
process.WeutilizedLEDunits consisting
of the Warp10 (Quantum Devices, New-
ark, OH, USA) and the Gentlewaves
(Light Bioscience, Virginia Beach, VA,
USA) instruments. The PBM treatment
parameters for the Warp10 were wave-
length 670  15 nm delivering 50–
80 mW/cm2 (4–7.68 J/cm2) for 88  8
seconds, and for the Gentlewaves were
wavelengths of 590 8 nm at 4 mWand
790  60 nm at 0.6 mW, both for
35 seconds, pulsed at 2.5 Hz (250 mil-
liseconds on, 150 milliseconds oﬀ) deliv-
ering 0.1 J/cm2/treatment.
All subjects were treated in both eyes
with the two devices used sequentially
at each treatment visit in nine sessions
over a 3-week period. The treatment
parameters delivered to the subjects
were identical at each session.
Study variables
The primary clinical eﬃcacy end-points
were change from BL in BCVA
and CS. The anatomical end-points
were change in SD-OCT and FAF
parameters.
All subjects were assessed with stan-
dardized ETDRS BCVA at a 4-m
distance (Precision Vision, Woodstock,
IL, USA) recorded as correct letters
scored. The letter score reported con-
forms to the WHO ICO report –
Sydney April 2002 with a scale of 100
correct letters equivalent to logMAR:
0, decimal: 1.0 and Snellen: 20/20.
Contrast sensitivity was assessed at
1.5, 3.0 and 6.0 cycles per degree
(cpd) (Stereo Vision Optec 6500; func-
tional acuity contrast test (FACT))
recorded as log CS for each cycle per
degree. Subjects were tested by the
same examiner at all visits under iden-
tical conditions in his private practice
oﬃce.
Subjects were assessed with 20 9 20
high-resolution SD-OCT volume scans
consisting of 25 section scans (250 lm
distance between each scan, nine frames
averaged) and with 488-nm FAF (Spec-
tralis OCT, Heidelberg Engineering,
Heidelberg, Germany). Subsequent
SD-OCT scans were performed using
the TruTrackTM (Heidelberg Engineer-
ingGmbH,Heidelberg,Germany) func-
tion to allow exact comparison of retina
and drusen volume. Measurements
included aligned mean central retinal
thickness (CRT), aligned mean retinal
volume (RV), GA lesion area, drusen/
reticular pseudodrusen (RPD) volume
and mean central drusen/RPD thick-
ness.
Optical coherence tomography (OCT)
and FAF scans were carefully reviewed
by an independent imaging expert for
the presence of drusen, RPD, GA,
vitelliform lesions and for irregularity
and disruption of the external limiting
membrane (ELM), ellipsoid zone (EZ)
and interdigitation zone (IZ) at each
visit. Fundus autoﬂuorescence images
were reviewed for the presence of GA
and vitelliform lesions.
Drusen in SD-OCT scans were
deﬁned as focal deposits of divergent
reﬂectivity and of variable size between
the RPE and the Bruch membrane
(Spaide & Curcio 2010). Drusenoid
RPE detachments, deﬁned as RPE
elevations ≥350 lm, were included in
the drusen volume measurements.
Reticular pseudodrusen (RPD) were
deﬁned as small hyper-reﬂective depos-
its located in the subretinal space
(Spaide & Curcio 2010). Geographic
atrophy on SD-OCT was identiﬁed
when there was absence/loss of the
RPE, the EZ and ELM together with
enhanced choroidal signal and concomi-
tant loss of the outer plexiform layer
(Sayegh et al. 2011). Vitelliform lesions
were identiﬁed when there were homo-
genous hyper-reﬂective lesions located
in the subretinal space (Chowers et al.
2015).
The individual retinal layers were
automatically segmented with the IN-
BUILT software (1.9.10.0, Heidelberg
Engineering, Germany) (Ctori &
Huntjens 2015). The segmentation
line of the Bruch’s membrane and
the internal limiting membrane was
inspected on each scan for correct
alignment and manually corrected if
needed to achieve valid RV and CRT
values. The automated, adjusted seg-
mentation line of the RPE was carefully
examined for exact drusen alignment
in each scan and in cases of incorrect
segmentation adjusted (Fig. 1). The
INBUILT software then automatically
(A) (B) (C)
Fig. 1. Representative images from two diﬀerent patients showing characteristic pathologic changes. Semi-automated segmentation in optical
coherence tomography (OCT) and geographic atrophy (GA) assessment in fundus autoﬂuorescence (FAF) were performed. The left image (A)
displays a representative drusen volume map of an AREDS 3 patient. Colour bars indicate ascending thickness values starting with 0 lm (black). The
image in the middle (B) demonstrates the drusen alignment in one representative OCT section scan of the same patient. The right image (C) illustrates
the assessment of the GA area using FAF at 488 nm wavelength in a patient with central involving GA of an AREDS 4 patient. The GA is measured
by manually marking the area of homogenous hypo-autoﬂuorescence using the INBUILT Heidelberg software (yellow line).
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calculated the total drusen volume
and the mean central 1-mm drusen
thickness within the ETDRS grid
between the Bruch’s membrane and
the ﬁtted RPE segmentation line
(Fig. 1).
A 488-nm FAF image was employed
to quantitatively assess GA. The area
of homogenous hypo-autoﬂuorescence
on the FAF BL and subsequent images
were manually marked using the IN-
BUILT ‘draw’ command of the Heidel-
berg software. Analysis of the absolute
GA lesion area as well as the square
root of the area was used in order to
allow growth comparison independent
of initial lesion size (Fig. 1) (Yehoshua
et al. 2011).
Statistical analyses
Statistical analyses were performed
using R (The R Project for Statistical
Computing; https://www.r-project.org)
version 3.0 or higher. Linear mixed-
eﬀects analyses were performed using
the R package nlme. Graphs were
generated using the R package ggplot2.
Data were analysed using random
intercept models with month as ﬁxed
eﬀect, subjects as random eﬀects and
eye nested within subject. The random
eﬀects model is analogous to a paired t-
test or repeated-measures analysis, but
controls for correlation of treatment
eﬀects between eyes within subjects.
We ﬁt linear mixed-eﬀects models
accounting that the observations of
eyes are not fully independent of one
another as pairs of eyes are from
the same subject. Two-sided p-values
<0.05 were considered statistically sig-
niﬁcant.
Results
The study evaluated 42 eyes from 24
subjects, 66–95 years of age (mean
78.0  7.83). There were 15 females
and 9 males. Baseline AMD disease
demographics are presented in Table 1.
Thirteen subjects (31%) presented with
GA of which nine subjects (21%) had
deﬁnite foveal involvement visible on
SD-OCT and FAF.
Baseline values of clinical and mor-
phological parameters are given in
Table 1.
All subjects had been taking
AREDS supplementation prior to the
intervention, and no changes were
made to their current dosing regimen
during the observational period.
Functional outcome measures of
BCVA and CS showed a signiﬁcant
positive eﬀect immediately following
the treatment (Table 2, Fig. 2). Mean
ETDRS BCVA score improved by 5.9
letters immediately post-treatment with
a signiﬁcant diﬀerence (p < 0.001) that
remained at a statistically signiﬁcant
level at visit 2 (p < 0.001; Table 2,
Fig. 2). A total of 11.9% of eyes treated
Table 1. Baseline Disease Distribution accord-
ing to AREDS Classiﬁcation, and Study
Outcome Measures.
Baseline disease distribution according
to AREDS classiﬁcation
AREDS classiﬁcation
Number of
eyes (%)
AREDS 2 9 (21%)
AREDS 3 20 (48%)
AREDS 4 13 (31%)
GA 13 (31%)
RPD 28 (67%)
Baseline clinical and functional
outcome measures
Study variables at BL (units) Mean  SD
ETDRS (letters) 86.29  11.36
CS 1.5 CPD (log CS) 1.36  0.17
CS 3.0 CPD (log CS) 1.50  0.23
CS 6.0 CPD (log CS) 1.54  0.20
Drusen volume (mm3) 0.46  0.14
Central drusen
thickness (lm)
35.12  36.58
GA area (mm2) 7.01  5.22
CRT (lm) 278.67  47.60
RV (mm3) 8.04  0.78
RPD = reticular pseudodrusen, SD = standard
deviation, ETDRS = early treatment diabetic
retinopathy study, CS = contrast sensitivity,
CPD = cycles per degree, log CS = log contrast
sensitivity, GA = geographic atrophy, CRT
= central retinal thickness,RV = retinal volume.
Table 2. Summary table of results.
Measure Comparison Letter score increase p-value
BCVA letter score BL to V1 +5.90 <0.001
BCVA letter score BL to V2 +5.14 <0.001
Measure Comparison Log CS increase p-value
CS 1.5 CPD BL to V1 +0.102 0.0113
CS 1.5 CPD BL to V2 +0.080 0.0558
CS 3.0 CPD BL to V1 +0.109 0.0224
CS 3.0 CPD BL to V2 +0.166 0.0155
CS 6.0 CPD BL to V1 +0.117 0.0029
CS 6.0 CPD BL to V2 +0.10 0.0360
Measure Comparison mm3 decrease p-value
Drusen volume BL to V1 0.024 <0.001
Drusen volume BL to V2 0.029 0.0206
Measure Comparison lm change p-value
Central drusen thickness BL to V1 3.78 <0.001
Central drusen thickness BL to V2 0.34 0.8781
CRT BL to V1 0.36 0.6872
CRT BL to V2 3.39 0.1422
GA area Comparison mm change p-value
GA square root BL to V1 0.021 0.2043
GA square root BL to V2 0.026 0.1618
Measure Comparison mm3 decrease p-value
RV BL to V1 0.066 0.1133
RV BL to V2 0.049 0.4639
BL = baseline, GA = geographic atrophy, early treatment diabetic retinopathy study letter score
(BCVA = best-corrected visual acuity), CS = contrast sensitivity at 1.5, 3.0 and 6.0 cycles per
degree (CPD, log units), drusen volume reduction (mm3), central retinal drusen thickness (lm),
retinal volume (RV, mm3) and central retinal thickness (CRT, lm).
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gained more than two lines
(≥11 ETDRS letters) and 59.5% of
eyes achieved more than a one line
increase from BL at visit 1 (Fig. 2).
Contrast sensitivity was signiﬁcantly
improved at 1.5, 3.0 and 6.0 CPD at
visit 1 immediately post-treatment with
p-values of 0.01, 0.02 and 0.003, respec-
tively (Table 2, Fig. 2). There was a
signiﬁcant correlation between CS and
VA beneﬁts (Pearson = 0.54; Spear-
man = 0.6).
Further subgroup analysis of the
BCVA data was employed to evaluate
whether the BL score is indicative of
the magnitude of change for potential
improvement following PBM treat-
ment. Although the linear regression
analysis of the change in BCVA as a
function of BL revealed that the BL
score was not associated with the
increase in visual acuity (r2 = 0.049,
p = 0.16), the majority of responders
with greater than ﬁve letters improve-
ment had a BL score of between 70 and
89 letters (Snellen equivalent of 20/80–
20/32) (Fig. 3). This group also had the
greatest number of responders with a
15 or more letter gain. Patients with
better (≥90 letters) or lower (60–69
letters) BL scores were less likely to
gain more than ﬁve letters (Fig. 4).
Outcome measures of drusen volume
and central drusen thickness showed a
signiﬁcant reduction immediately fol-
lowing the 3-week treatment at visit 1
(p < 0.001). At visit 2, drusen volume
was still signiﬁcantly reduced (p = 0.02;
Table 2, Fig. 2). There were no signiﬁ-
cant changes in CRT, GA area or RV
during the observational period.
Representative segmented section
scans illustrating the drusen regression
following therapy is given in Figs 4
and 5.
None of the patients developed new
wet AMD or GA during the study
analysis period of 3 months.
Discussion
ThepreviousTORPAstudywas the ﬁrst
to show improvement in functional
parameters using LED light sources
for dry AMD subjects (Merry et al.,
PBM for dry AMD, ARVO, 2012).
Signiﬁcant improvement in BCVA and
CS was observed immediately following
PBMandwasmaintained at 1 year. The
results from the current study further
corroborate the improvement in func-
tional measures (BCVA and CS) seen in
the earlier TORPA study and demon-
strate the beneﬁts of PBM to signiﬁcant
improvement in anatomical end-points
of the disease. This has not been studied
in any previous PBM intervention for
AMD.
Fig. 2. (A) Photobiomodulation (PBM) leads to signiﬁcant improvement in early treatment
diabetic retinopathy study (ETDRS) letter score (absolute plot – jitter) in individual subjects. The
bold dotted line indicates the overall mean. (B) Contrast sensitivity (CS; 3.0 CPD) in logCS change
from baseline (BL) following PBM treatment (absolute plot – jitter) in individual subjects. The
bold dotted line indicates the overall mean. (C) This panel indicates the percentage of eyes
presenting with one, two and three line ETDRS letter gain at visit 1 ( = immediate post-treatment,
3 weeks after BL). (D) Drusen volume measurements in mm3 change from BL following PBM
treatment (absolute plot – jitter) in individual subjects. The bold dotted line indicates the overall
mean.
Fig. 3. Visual acuity change in magnitude categorized by baseline (BL) VA scores. Eyes with a BL
VA letter score of between 70 and 89 (Snellen equivalent of 20/80–20/32) appeared to respond to
photobiomodulation treatment with a high percentage gaining greater than ﬁve letters. Eyes with
lower (60–69 letters) or higher (≥90 letters) BL VA letter score were less likely to gain more than
ﬁve letters.
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Best-corrected visual acuity in dry
AMD may remain stable or slowly
decline without rapid vision loss.
Therefore, a small visual gain in this
patient cohort is clinically relevant. In
this case series, BCVA improved in
over 90% of subjects with 59.5%
achieving better than ﬁve letters and
11.9% achieving better than 10 letters
on ETDRS BCVA testing, representing
signiﬁcant improvement in visual func-
tion. Early treatment diabetic retinopa-
thy study BCVA testing measurements
with a logMAR score change of 0.1
(ﬁve letters) has been shown to be
Fig. 4. Representative example of an eye categorized as AREDS 3 with mainly convex, homogenous and low reﬂective drusen larger than 125 lm.
Baseline (Top) shows a drusen volume of 0.39 mm3 with a mean central 1-mm drusen with thickness of 29 lm. Black numbers indicate the mean
drusen thickness of each early treatment diabetic retinopathy study subgrid and red numbers indicate the corresponding drusen volume (mm3).
Bottom: Follow-up examination at visit 1. Overall drusen volume as well as mean central drusen thickness has signiﬁcantly decreased without new
formation of geographic atrophy or disruption of the photoreceptor layers.
Fig. 5. An individual cut segmented subtraction scan showing signiﬁcant drusen regression at 3 months following the treatment course.
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statistically signiﬁcant and clinically
relevant (Elliott & Sheridan 1988).
Based on 95% conﬁdence intervals, a
change in acuity of logMAR 0.2 (10
letters) from BL is unlikely to be
related to measurement variability
(Beck et al. 2003).
Interestingly, it would appear that
those with good to fair vision (20/30–
20/80) beneﬁted the most from PBM
therapy. However, patients with BCVA
both better and worse than this group
at BL also showed beneﬁt. This seems
reasonable considering the ceiling eﬀect
in patients with a BCVA better than
20/32 and the fact that patients with a
BL score worse than 20/80 already
exhibit irreversible damage of the outer
retina in the fovea. Improvements in
CS were also signiﬁcant and correlated
to the improvements in BCVA.
The signiﬁcant drusen reduction in
association with functional improve-
ment is particularly compelling. Our
data clearly show a decrease in drusen
volume and mean central drusen thick-
ness. Although drusen formation and
regression are in a constant process of
change, we know from previous studies
that the drusen area tends to increase
even during a short period of time
(Gregori et al. 2014). A short-term
follow-up study analysing drusen area
progression over 6 months has demon-
strated a progression of 0.031 and
0.029 mm2 on SD-OCT and CF,
respectively (Gregori et al. 2014). Our
data showed a mean regression of
drusen volume of 0.03 mm3 over a
period of 3 months. While drusen
regression and resolution can leave
behind GA (Suzuki et al. 2015), drusen
can also collapse and vanish without
contributing to further photoreceptor
and RPE irregularity and loss. In this
study, none of the eyes developed new
onset of EZ or IZ irregularities or new
formation of RPE loss, indicating that
drusen regressed without contributing
to new GA formation.
Increase in drusen area (Sarraf et al.
1999) has previously found to be a
signiﬁcant predictive factor for the onset
of late-stage AMD and the presence of
RPD has been associated with a higher
risk of late-stage AMD (Marsiglia et al.
2013; Alten & Eter 2015). Patients with
RPD in this case series showed similar,
signiﬁcant treatment responses suggest-
ing regression of disease.
Higher power lasers as well as sub-
threshold lasers have been used to
aﬀect drusen regression but did not
show evidence to reduce the risk of
developing CNV or GA. A meta-
analysis on laser studies evaluating
the functional and morphological eﬃ-
cacy of laser treatment in AMD has
shown that laser may be eﬀective to
induce drusen reduction, but does not
seem to reduce the development of
CNV. A case series and a study utiliz-
ing subthreshold micropulse laser and
nanosecond laser, respectively, in dry
AMD patients have shown partial
drusen regression but with no improve-
ment in BCVA (Rykov et al. 2015).
In contrast to laser treatment, PBM
utilizes very low energy levels causing
no tissue damage. Photobiomodulation
stimulates cellular processes that pro-
vide an approach to target the under-
lying degenerative pathology with
disease-modifying potential. A recent
review paper of PBM in retinal diseases
has reported that the literature sup-
ports the conclusion that the low cost
and non-invasive nature of PBM cou-
pled with the ﬁrst promising clinical
reports and the numerous preclinical
studies in animal models make PBM
well poised to become an important
player in the treatment of retinal dis-
orders (Geneva 2016).
A randomized control group was
not included as these patients were
being treated in an oﬀ-label protocol
with commercial instruments that were
limited in ﬂexibility to modify or mask
treatments. Consideration was given to
using just one of the subjects’ eyes as a
control; however, this was not accept-
able to patients receiving the treatment
and there is a possibility of systemic
signalling and improvement in remote
tissues with PBM. Therefore, it is most
desirable to completely separate active
patients from control in future studies.
Examiner bias was mitigated by rigor-
ously ensuring identical conditions at
each visit for all patients with an
experienced physician. Subgroup anal-
ysis should be considered preliminary
and intriguing as the subject numbers
are limited; however, signiﬁcant posi-
tive conclusions can be drawn on the
main end-points of ETDRS BCVA, CS
and drusen reduction.
The data presented have formed the
basis for a National Eye Institute
partially funded grant to support a
Health Canada- and IRB-approved,
randomized, placebo (sham treatment),
double-masked prospective, clinical
trial that is currently enrolling in
Toronto. The LIGHTSITE I trial is
looking at similar clinical and anatom-
ical end-points that are presented here
with the addition of microperimetry
and VFQ-25.
The present study demonstrated
drusen reduction utilizing selected mul-
tiple wavelengths of LED sourced light
that are non-thermal and shown to
have anti-inﬂammatory, antioxidative,
neuroprotective and anti-apoptotic ben-
eﬁts as evident in several in vitro and
in vivo ocular models (Eells et al. 2003;
Albarracin et al. 2011; Tang et al. 2013;
Gkotsi et al. 2014). It is the com-
bination of anatomical changes coinci-
dent with functional improvements
that is most promising for PBM as a
novel treatment for dry AMD. The
clinical results to date provide the
foundation for a novel non-invasive
approach to the treatment of dry
AMD.
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